Τίτλος:
Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
We evaluated bortezomib induced peripheral neuropathy (BIPN) characteristics in an attempt to better clarify the type, grade, duration and reversibility of neuropathy as well as investigate possible peripheral neuropathy (PN) risk factors and detect the best way to manage it. We calculated the grading of neuropathy using the Total Neuropathy Score reduced version (TNSr) in a series of 51 patients with relapsed/refractory multiple myeloma treated with bortezomib. Seventy percent developed clinical PN. BIPN, although manageable, is frequently underestimated in patients treated with bortezomib intravenously. Continuous follow-up and management of PN are needed to avoid quality of life impairment. © 2014 Informa UK, Ltd.
Συγγραφείς:
Zaroulis, C.K.
Chairopoulos, K.
Sachanas, S.P.
Maltezas, D.
Tzenou, T.
Pessach, I.
Koulieris, E.
Koutra, E.
Kilindireas, K.
Pangalis, G.A.
Kyrtsonis, M.-C.
Περιοδικό:
Clinical Lymphoma Myeloma and Leukemia
Εκδότης:
Informa Healthcare
Λέξεις-κλειδιά:
bortezomib; dexamethasone; antineoplastic agent; boronic acid derivative; bortezomib; pyrazine derivative, adult; aged; Article; cancer patient; cancer recurrence; disease duration; disease severity; female; human; major clinical study; male; multiple cycle treatment; multiple myeloma; peripheral neuropathy; priority journal; quality of life; risk factor; scoring system; Total Neuropathy Score; complication; follow up; middle aged; multiple myeloma; neurologic examination; Peripheral Nervous System Diseases; very elderly, Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neurologic Examination; Peripheral Nervous System Diseases; Pyrazines; Risk Factors
DOI:
10.3109/10428194.2013.873535
